Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A | P35348 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 5/20 | 0.48 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.48 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.48 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.46 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.44 |
| ▸ | PPARG | P37231 | 7/20 | 0.44 |
| ▸ | PPARD | Q03181 | 7/20 | 0.44 |
| ▸ | PPARA | Q07869 | 7/20 | 0.44 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | TLR2 | O60603 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | FABP4 | P15090 | 2/20 | 0.44 |
| ▸ | SLC22A6 | Q4U2R8 | 2/20 | 0.44 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11412060 | 0.98 | ADRA1A (0.55) | ADRA1ALMNAPRMT1TSHRNFKB1 | |
| SCHEMBL7787451 | 0.98 | ADRA1A (0.55) | ADRA1ALMNAPRMT1TSHRNFKB1 | |
| SCHEMBL23901607 | 0.98 | ADRA1A (0.55) | ADRA1ALMNAPRMT1TSHRNFKB1 | |
| SCHEMBL14558118 | 0.98 | ADRA1A (0.55) | ADRA1ALMNAPRMT1TSHRNFKB1 | |
| SCHEMBL14558105 | 0.98 | ADRA1A (0.55) | ADRA1ALMNAPRMT1TSHRNFKB1 | |
| SCHEMBL5255471 | 0.93 | LMNA (0.46) | ADRA1ALMNAPRMT1TSHRNFKB1 | |
| Stearic Acid SCHEMBL28319931 | 0.90 | GPR84 (0.63) | TSHRAKR1B1GPR84PPARGPPARD | |
| Stearic Acid SCHEMBL28318872 | 0.90 | GPR84 (0.63) | TSHRAKR1B1GPR84PPARGPPARD | |
| Stearic Acid SCHEMBL28318864 | 0.90 | GPR84 (0.63) | TSHRAKR1B1GPR84PPARGPPARD | |
| Stearic Acid SCHEMBL28319943 | 0.90 | GPR84 (0.63) | TSHRAKR1B1GPR84PPARGPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240200049-A1 | COMPOSITIONS AND METHODS OF USE THEREOF FOR MAKING POLYPEPTIDES WITH MANY INSTANCES OF NONSTANDARD AMINO ACIDS | YALE UNIVERSITY | 2024-06-20 | — | — | US | disclosed |
| US-11873291-B2 | Quinoline cGAS antagonist compounds | IMMUNESENSOR THERAPEUTICS, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| US-20230357158-A1 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2023-11-09 | — | — | US | disclosed |
| US-11649446-B2 | Compositions and methods of use thereof for making polypeptides with many instances of nonstandard amino acids | YALE UNIVERSITY (US) | 2023-05-16 | — | — | US | disclosed |
| US-20230123569-A1 | COMPOUNDS AS AUTOTAXIN INHIBITORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | LIGACHEM BIOSCIENCES INC. (KR) | 2023-04-20 | — | — | US | disclosed |
| US-11548883-B2 | Compounds as autotaxin inhibitors and pharmaceutical compositions comprising the same | LEGOCHEM BIOSCIENCES, INC. (KR) | 2023-01-10 | — | — | US | disclosed |
| US-10961242-B2 | Compounds as autotaxin inhibitors and pharmaceutical compositions comprising the same | LEGOCHEM BIOSCIENCES, INC. (KR) | 2021-03-30 | — | — | US | disclosed |
| US-20200407350-A1 | NOVEL COMPOUNDS AS AUTOTAXIN INHIBITORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | LIGACHEM BIOSCIENCES INC. (KR) | 2020-12-31 | — | — | US | disclosed |
| US-20200190500-A1 | COMPOSITIONS AND METHODS OF USE THEREOF FOR MAKING POLYPEPTIDES WITH MANY INSTANCES OF NONSTANDARD AMINO ACIDS | YALE UNIVERSITY | 2020-06-18 | — | — | US | disclosed |
| US-20200172542-A1 | NOVEL COMPOUNDS AS AUTOTAXIN INHIBITORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | LIGACHEM BIOSCIENCES INC. (KR) | 2020-06-04 | — | — | US | disclosed |
| US-20160355802-A1 | Compositions and Methods Of Use Thereof For Making Polypeptides With Many Instances Of Nonstandard Amino Acids | YALE UNIVERSITY | 2016-12-08 | — | — | US | disclosed |
| US-9034850-B2 | Gonadotropin releasing hormone receptor antagonist, preparation method thereof and pharmaceutical composition comprising the same | SK CHEMICALS CO., LTD. (KR) | 2015-05-19 | — | — | US | disclosed |
| US-20130137661-A1 | Gonadotropin Releasing Hormone Receptor Antagonist, Preparation Method Thereof And Pharmaceutical Composition Comprising The Same | SK CHEMICALS CO. LTD. (KR) | 2013-05-30 | — | — | US | disclosed |
| WO-2011095218-A1 | TEMPLATE-FIXED PEP TIDOMIME TICS WITH CXCR7 MODULATING ACTIVITY | POLYPHOR AG (CH) | 2011-08-11 | — | — | WO | disclosed |
| US-7419983-B2 | e.g. 3-[{hydroxycarbonylpropyl-amino}-2-phenylethyl]-5-(2-fluoro-3-methoxyphenyl)-1-[2-fluoro-6-(trifluoromethyl)benzyl]-6-methylpyrimidine-2,4(1H,3H)-dione; sex-hormone related diseases; anticarcinogenic agent; endometriosis, uterine fibroids, polycystic ovarian disease | NEUROCRINE BIOSCIENCES, INC. (US) | 2008-09-02 | — | — | US | disclosed |
| US-20070191403-A1 | GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO | NEUROCRINE BIOSCIENCES, INC. (US) | 2007-08-16 | — | — | US | disclosed |
| US-20070054909-A1 | VLA-4 inhibitor compounds | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-03-08 | — | — | US | disclosed |
| US-7179819-B2 | VLA-4 inhibitor compounds | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-02-20 | — | — | US | disclosed |
| US-7176211-B2 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2007-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130137661-A1 | Gonadotropin Releasing Hormone Receptor Antagonist, Preparation Method Thereof And Pharmaceutical Composition Comprising The Same | GNRHR, GHRHR, LHCGR | ADRA1A 360/4885LMNA 3089/4885PRMT1 2624/4885 |
| US-11548883-B2 | Compounds as autotaxin inhibitors and pharmaceutical compositions comprising the same | ENPP2, PLA2G10, LPCAT1 | ADRA1A 2228/4885LMNA 4301/4885PRMT1 4249/4885 |
| US-20070054909-A1 | VLA-4 inhibitor compounds | VCAM1, ITGB4, ICAM1 | ADRA1A 221/4885LMNA 2312/4885PRMT1 1619/4885 |
| US-11873291-B2 | Quinoline cGAS antagonist compounds | CGAS, GLS2, GLS | ADRA1A 220/4885LMNA 1681/4885PRMT1 2995/4885 |
| US-20230123569-A1 | COMPOUNDS AS AUTOTAXIN INHIBITORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | ENPP2, PLA2G10, LPCAT1 | ADRA1A 2228/4885LMNA 4301/4885PRMT1 4249/4885 |
| US-20230357158-A1 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | CGAS, GLS2, GLS | ADRA1A 220/4885LMNA 1681/4885PRMT1 2995/4885 |
| US-10961242-B2 | Compounds as autotaxin inhibitors and pharmaceutical compositions comprising the same | ENPP2, PLA2G10, LPCAT1 | ADRA1A 2228/4885LMNA 4301/4885PRMT1 4249/4885 |
| US-20070191403-A1 | GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO | GNRHR, GHRHR, LHCGR | ADRA1A 165/4885LMNA 3233/4885PRMT1 596/4885 |
| US-20200407350-A1 | NOVEL COMPOUNDS AS AUTOTAXIN INHIBITORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | ENPP2, LPCAT1, PLA2G10 | ADRA1A 2065/4885LMNA 3974/4885PRMT1 4276/4885 |
| US-20200172542-A1 | NOVEL COMPOUNDS AS AUTOTAXIN INHIBITORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | ENPP2, LPCAT1, PLA2G10 | ADRA1A 2065/4885LMNA 3974/4885PRMT1 4276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.